Skip to content

Clinical observation on the treatment of chloasma by auricular acupoint bloodletting therapy

Clinical observation on the treatment of chloasma by auricular acupoint bloodletting therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000550
Enrollment
Unknown
Registered
2026-03-18
Start date
2020-09-30
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chloasma

Interventions

Control group:External application of auricular pressure pills treatment was used
Treatment group :auricular acupoint bloodletting therapy

Sponsors

Beijing Aerospace General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Compliance with the "Diagnostic and Therapeutic Criteria for Melasma and Vitiligo (2010 Edition)" formulated by the Pigmentary Disorders Study Group of the Dermatological and Venereal Diseases Professional Committee of the China Association of Integrative Medicine [6]: The skin lesion presents as light brown to dark brown patches on the face usually symmetrically distributed without inflammatory manifestations or scales; the condition may be seasonal often worse in summer and lighter in winter; exclusion of post-inflammatory hyperpigmentation naevus fusco-caeruleus zygomaticus Riehl's melanosis pigmented lichen planus and other skin diseases. (2) Female; aged 20 to 55 years; disease duration of 0.5 to 10 years. (3) No mental disorders affecting cognitive function with good communication skills. (4) Ability to adhere to the planned course of treatment and comply with lifestyle guidance recommendations regarding sun protection. (5) Patients have read and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Age 55 years; (2) Women who are preparing for pregnancy, pregnant, or taking oral contraceptives; (3) Having taken other drugs affecting endocrine function within the past six months; (4) Suffering from serious primary diseases of the heart, liver, kidney, or hematopoietic system, or mental illness; (5) Known allergy to any component of the trial drug. (6) Failure to comply with or interruption of the treatment protocol of this trial; (7) Failure to meet the above inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Melasma Area and Severity Index(MASI);

Secondary

MeasureTime frame
Dermatology life quality index;TCM symptom integral table;Physician's Global Assessment (PGA);Patient Global Assessment (PtGA) ;

Countries

China

Contacts

Public ContactYingchaoWANG

Beijing Aerospace General Hospital

wangyingchaobear@sina.com15811422089

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026